Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences IncfiledCriticalGilead Sciences Inc
Publication of AR118477A1publicationCriticalpatent/AR118477A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen compuestos para usar en el tratamiento o prevención de la infección por el virus de la inmunodeficiencia humana (VIH). Los compuestos tienen la fórmula (1), incluyendo estereoisómeros y sales farmacéuticamente aceptables del mismos, en la que R¹, R², L, W¹, W², X, Y y Z son como se define en el presente documento. También se describen métodos asociados con la preparación y uso de tales compuestos, así como composiciones farmacéuticas que comprenden tales compuestos.Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the formula (1), including stereoisomers and pharmaceutically acceptable salts thereof, wherein R¹, R², L, W¹, W², X, Y and Z are as defined herein. Methods associated with the preparation and use of such compounds are also described, as well as pharmaceutical compositions comprising such compounds.
ARP200100812A2019-03-222020-03-25
CARBAMOYLPYRIDONE BRIDGE TRICYCLIC COMPOUNDS AND THEIR PHARMACEUTICAL USE
AR118477A1
(en)
Compounds derived from polycyclic carbamoylpyridone; pharmaceutical composition comprising them; and its use for the treatment of a hiv infection in a human who has or is at risk of having the infection.